BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Acute lymphoblastic leukemia clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for acute lymphoblastic leukemia: 109 (68 sponsors; 10 newly posted in the last 180 days, 6 stopped in the last 180 days; 5 new-entrant sponsors). Momentum score 5.5, rank 87 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 3, Phase 1 33, Phase 2 46, Phase 3 10, Phase 4 0, N/A 17.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Amgen AMGN5P3 2, P2 300
Novartis Pharmaceuticals NVS7P2 3, NA 2, P1 1, P3 102
Orca Biosystems, Inc.3P3 1, P1 200
AbbVie ABBV2P3 1, P2 100
Ascentage Pharma Group Inc. AAPG2P3 1, P1 100
Merck Sharp & Dohme LLC MRK2P2 1, P3 100
Acacia Pharma Ltd1P3 100
CSL Behring new entrant1P3 110
Takeda TAK1P3 100
Chongqing Precision Biotech Co., Ltd5P2 1, NA 1, P1 311
Hebei Senlang Biotechnology Inc., Ltd.5P1 1, P2 2, NA 201
PersonGen BioTherapeutics (Suzhou) Co., Ltd.4P1 2, P2 1, EARLY_P1 111
AstraZeneca AZN3P2 300
Juventas Cell Therapy Ltd.3P2 2, NA 100
Miltenyi Biomedicine GmbH3NA 2, P1 110
Ossium Health, Inc.3NA 2, P2 110
Allotera Therapeutics2P2 1, NA 101
Autolus Limited AUTL2P2 1, P1 100
Bellicum Pharmaceuticals2P2 200
Kite, A Gilead Company2P1 1, P2 100
Pfizer PFE2NA 1, P2 100
Sichuan Baili Pharmaceutical Co., Ltd.2P1 200
Syndax Pharmaceuticals SNDX2P1 1, P2 110
Allterum Therapeutics, Inc1P1 100
AvenCell Therapeutics, Inc.1NA 100

New-entrant sponsors: CSL Behring.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-30 est.P2Allotera TherapeuticsNCT06514794 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphomarecruiting125
2026-12-31 est.P1/P2Chongqing Precision Biotech Co., LtdNCT04781634 a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALLB-ALLrecruiting40
2026-12-31 est.P1/P2Excyte Biopharma LtdNCT06580301 Study of YK012 in B-cell Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemiarecruiting46

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-16P1/P2Cellectis S.A. CLLSNCT04150497 Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)B-cell Acute Lymphoblastic Leukemiaactive not recruiting45
2026-07-14P1/P2Ossium Health, Inc.NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignAcute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; Aactive not recruiting12

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "acute lymphoblastic leukemia"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.